Difference between revisions of "Ultrasound CEUS BC"
Jump to navigation
Jump to search
| Line 35: | Line 35: | ||
Vendor Press Release | Vendor Press Release | ||
| − | *[[ | + | *[[Media:US-20160404-PR_221236_LUMASON_Liver-PR_0.pdf|FDA Approval for LUMASON® Press Release]] |
*[[Media: QIBA Ultrasound Biomarkers Meeting, 03.29.2012-Dr. Hoyt.pdf|QIBA Ultrasound Biomarkers Meeting, 03.29.2012-Dr. Hoyt Presentation]] | *[[Media: QIBA Ultrasound Biomarkers Meeting, 03.29.2012-Dr. Hoyt.pdf|QIBA Ultrasound Biomarkers Meeting, 03.29.2012-Dr. Hoyt Presentation]] | ||
*[[Media:x.pdf|text ]] | *[[Media:x.pdf|text ]] | ||
Revision as of 18:49, 27 May 2016
- Co-chairs: • Michalakis (Mike) A. Averkiou, PhD; Richard G. Barr, MD, PhD
- Secretary: Julie Lisiecki
- Roster: (Roster)
Project Snapshot
The Contrast Enhanced Ultrasound Biomarker Committee (CEUS BC) seeks to develop a quantitative imaging profile for CEUS imaging.
Under consideration:
Meetings/Call Summaries
Working Documents
Statistical Reference Documents
Workflow Documents
Historical Background - Formation of the Group
Reference Materials
Original Proposal to the QIBA Steering Committee
Vendor Press Release